A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

NCT00540670 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: E5555 50 mg
DRUG: E5555 100 mg
DRUG: E5555 200 mg
DRUG: Placebo

Sponsor

Eisai Co., Ltd.